Business Wire

ADVA

9.6.2022 09:02:06 CEST | Business Wire | Press release

Share
ADVA simplifies uCPE rollout with industry’s first software-as-a-service MANO

ADVA (FSE: ADV) today launched the market’s first NFV management and orchestration (MANO) platform delivered through a software-as-a-service (SaaS) model. ADVA’s Ensemble SaaS MANO simplifies and accelerates uCPE deployments, ensuring faster time to revenue for communication service provider (CSP) and enterprise customers. Hosted in the public cloud and managed by ADVA or its partners, the offering provides access to critical management tools while delivering significant cost savings. It enables CSPs and enterprises to harness the opportunities of virtualization without major investment in resources or training.

“MANO is key to NFV and uCPE success. But for many operators, leveraging a solution that meets business and operational requirements without massive investment has been a real challenge. That all changes with the introduction of our Ensemble SaaS MANO. Now CSPs, integrators and enterprises can access a MANO platform built from the ground up for the NFV domain in an easy, affordable way,” said Mike Heffner, GM of Edge Cloud, ADVA. “Our Ensemble SaaS MANO takes the agility and cost-efficiency of cloud-based services to the next level. For many customers, it will unlock the door to the full benefits of network virtualization.”

ADVA’s new Ensemble SaaS MANO can be purchased through a flexible, simple and success-based subscription model. It provides cost-efficient access to an open NFV MANO architecture that supports the rollout of secure virtualized service at scale across multiple locations. The unique way of accessing the solution enables customers to make major savings on operational expenditure and offers CSPs the opportunity to establish new business before investing upfront in uCPE infrastructure. What’s more, Ensemble SaaS MANO provides the ability to migrate from SaaS to a self-managed model if customers choose to make the switch in the future.

“By making our Ensemble MANO solution available as a SaaS offering, we’re empowering many more customers to seize the advantages of uCPE. It unlocks a range of new applications for enterprises and gives CSPs instant access to new revenue streams. And for our technology partners, it offers a way to deliver turn-key solutions and drive higher-value services to end customers,” commented Prayson Pate, CTO of Edge Cloud, ADVA. “Ensemble SaaS MANO creates a risk-free path to uCPE success. It will be key to helping businesses across the world achieve their virtualization vision.”

Further information on Ensemble SaaS MANO is available in these slides: https://adva.li/saas-mano-slides .

A live webinar will also be held on Wednesday, June 22 at 4 p.m. BST. Register here: https://attendee.gotowebinar.com/register/8081906767233987599 .

About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 12:00:00 CEST | Press release

$85M upfront financing, along with up to $255 million upon exercise of purchase warrants, is expected to fund ROBBIN1, Agenus' registrational Phase 3 trial of neoadjuvant botensilimab and balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer Transaction is structured to fund Agenus through key value-inflection points, including interim topline pathologic response data and interim and final event-free survival (EFS) analyses, with proceeds to fund Agenus operations through year-end 2031, assuming full warrant exercise ROBBIN target population in MSS colon cancer represents a >$7 billion addressable annual sales opportunity in the US for which no new therapies have been approved in over 20 years2,3 To focus resources on the neoadjuvant opportunity, Agenus is discontinuing financial support for the ongoing BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer Company to host conference call and webcast today at 8:30 a.m. ET Agenus Inc. (Nasdaq: AGEN), a leader in

Zayed Sustainability Prize Closes 2027 Submissions with Strong Global Participation13.7.2026 11:48:00 CEST | Press release

Over 10,000 entries from 177 countries mark the highest participation in the Prize’s historySubmissions increased 32% year-on-year, reflecting sustained local led momentum for scalable global impactThrough 139 winners, the Prize has positively impacted more than 411 million lives worldwide The Zayed Sustainability Prize, the UAE’s pioneering award for innovative solutions to global challenges, has officially closed submissions for its 2027 awards cycle, receiving an unprecedented 10,233 entries from 177 countries across its six categories of Health, Food, Energy, Water, Climate Action and Global High Schools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713519403/en/ Zayed Sustainability Prize Closes 2027 Submissions with Strong Global Participation (Photo: AETOSWire) Now in its 18th year, the Prize continues to attract a diverse and growing pool of small and medium-sized enterprises, nonprofit organisations and high sc

Ant Group Open-Sources SingGuard-NSFA to Establish New Security Paradigms for Autonomous AI Agents13.7.2026 11:01:00 CEST | Press release

Ant Group’s AI Security Lab today announced the open-source release of SingGuard-NSFA, a specialized security guardrail framework designed specifically for autonomous AI agents. The framework secures agentic AI systems against operational threats like prompt injection, addressing critical vulnerabilities as AI transitions from passive content generation to active, autonomous execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712722454/en/ As AI agents rapidly move from research labs to business scenarios, the security landscape has fundamentally shifted. The explosive global adoption of open-source agent frameworks like OpenClaw, celebrated for their "one-click deployment" and "full-stack autonomy", has simultaneously exposed significant operational risks, including permission escalation and prompt injection. Industry frameworks, including the OWASP (Open Web Application Security Project) Top 10 for Agentic Applica

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types13.7.2026 10:00:00 CEST | Press release

- Treatment with latarcibart led to an 81% median reduction in annualized bleeding rate (ABR) across all bleeding categories and patient types with von Willebrand disease (VWD) - Latarcibart, administered via a once monthly subcutaneous dosing regimen, was shown to be safe and well tolerated over multiple doses in this study - Pivotal Phase 3 VIVID-6 trial evaluating latarcibart’s potential to be the first targeted therapy for VWD is currently enrolling Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, investigational monoclonal antibody for patients with von Willebrand disease (VWD). The data are being shared in an oral presentation today at the 34th Congress of the International Society on Thrombosis and Haemostasis (ISTH 2026 Congress) in Paris. Latarcibart modulates Protein S to improve hemostasis, potentially enhancing the body’s ability t

Europe’s Demand for Tech Services Accelerates in Q2, As Spending on AI and Managed Services Rises: ISG Index™13.7.2026 10:00:00 CEST | Press release

Combined market up 46%, led by 64% growth in cloud servicesManaged services up 21%, as companies seek cost savings to fund AI Demand for technology services in Europe continued to accelerate in the second quarter, as the region increasingly turns to managed services to reduce costs and cloud services to meet AI objectives, according to the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows second-quarter ACV for the combined market (both managed services and cloud-based as-a-service) soared 46 percent—its largest growth in eight years—to US $13.0 billion. The latest quarter adds to a string of three straight quarters in which growth has averaged 33 percent. “Europe has become the fastest-growing region for technology services, fueled not only by an increasin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye